Valuation : Monte Rosa Therapeutics, Inc.

Market Cap 1.2B 1.03B 979M 888M 1.67B 115B 1.67B 11.63B 4.47B 58.34B 4.51B 4.41B 184B P/E 2026 *
-9.36x
P/E 2027 * -7.42x
Enterprise Value 1.2B 1.03B 979M 888M 1.67B 115B 1.67B 11.63B 4.47B 58.34B 4.51B 4.41B 184B EV / Sales 2026 *
18.2x
EV / Sales 2027 * 21x
Free-Float
99.44%
Yield 2026 *
-
Yield 2027 * -
Sep. 08 Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon MT
Sep. 08 Monte Rosa Therapeutics Initiates Phase 2 Clinical Study for Vav1-Directed Molecular Glue Degrader MRT-6160 CI
Sep. 08 Monte Rosa to Receive $50 Million Milestone Payment From Novartis for Phase 2 Launch of MRT-6160 MT
Aug. 24 Monte Rosa Therapeutics Doses First Patient in Phase 2 Prostate Cancer Study MT
Aug. 24 Monte Rosa Therapeutics Doses First Patient In MODeFIRe-1 Phase 2 Study Of MRT-2359 In Combination With Apalutamide In Patients With AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer CI
Aug. 06 Monte Rosa Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
Aug. 06 Earnings Flash (GLUE) Monte Rosa Therapeutics, Inc. Reports Q2 Collaboration Revenue $9.0M, vs. FactSet Est of $12.9M MT
Jul. 31 Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial MT
Jul. 31 Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating MT
Jun. 29 Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell 2500 Growth Benchmark CI
Jun. 29 Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell Microcap Value Benchmark Index CI
Jun. 29 Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) dropped from Russell 2000 Value Benchmark CI
Jun. 29 Monte Rosa Therapeutics, Inc.(NasdaqGS:GLUE) added to Russell Microcap Growth Benchmark Index CI
1 day-1.75%
1 week+1.66%
Current month+0.93%
1 month-11.79%
3 months-22.84%
6 months-12.28%
Current year-10.27%
1 week 13.44
Extreme 13.44
14.87
1 month 13.12
Extreme 13.12
16.2
Current year 13.12
Extreme 13.12
25.77
1 year 6.06
Extreme 6.06
25.77
3 years 2.44
Extreme 2.44
25.77
5 years 2.44
Extreme 2.44
34.26
10 years 2.44
Extreme 2.44
45.56
Manager TitleAgeSince
Chief Executive Officer 55 2019-12-31
Chief Tech/Sci/R&D Officer - 2026-03-16
Chief Operating Officer 54 2021-02-28
Director TitleAgeSince
Director/Board Member 55 2019-12-31
Director/Board Member 49 2020-03-31
Director/Board Member 57 2020-05-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/16/26 Sell

Chief Executive Officer

-9,500 0.0112%
7/15/26 Exercice

Chief Operating Officer

13,053 0.0155%
7/6/26 Exercice

Chief Technology Officer

18,000 0.0213%
Change 5-day change 1-year change 3-year change Capi.($)
-1.75%+1.66%+192.52%+136.47% 1.2B
-0.71%-6.35%-2.99%+9.59% 45.48B
+0.21%-2.98%+337.74%+519.55% 43.68B
+1.74%-2.24%+39.82%+20.76% 43.09B
+1.38%-3.28%+6.84%+67.62% 39.4B
-1.44%-5.26%+8.97%+39.76% 31.91B
+0.87%-2.60% - - 17.31B
+0.75%-0.64%+19.75%+110.17% 16.4B
-0.31%-2.78%+10.78%+31.02% 14.24B
+1.93%-3.55%+82.00%+41.17% 13.28B
Average +0.27%-3.05%+77.27%+108.46% 26.6B
Weighted average by Cap. +0.40%-3.64%+75.14%+124.32%

Financials

2026 *2027 *
Net sales 65.89M 56.77M 53.76M 48.72M 91.41M 6.3B 91.87M 638M 246M 3.2B 247M 242M 10.12B 57.07M 49.17M 46.56M 42.2M 79.17M 5.45B 79.57M 553M 213M 2.77B 214M 210M 8.76B
Net income -152M -131M -124M -112M -211M -14.52B -212M -1.47B -566M -7.38B -571M -558M -23.33B -201M -173M -164M -149M -279M -19.22B -281M -1.95B -750M -9.78B -756M -739M -30.9B
Net Debt - -
Logo Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of novel and molecular glue degraders (MGDs). MGDs are small molecule drugs that employ the body’s natural protein destruction mechanisms to selectively degrade therapeutically relevant proteins. It has developed a proprietary and industry leading discovery engine, called Quantitative and Engineered Elimination of Neosubstrates (QuEEN) to enable its target centric MGD discovery and development approach and its rational design of MGD product candidates. Its product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1. MRT-2359 is in clinical development for potential use in MYC-driven tumors, including metastatic non-small cell lung cancer, small cell lung cancer, and neuroendocrine tumors. Its other product candidates include MRT-6160 and MRT-8102.
Employees
173
Date Price Change Volume
26-09-11 $14.07 -1.75% 1,173,907
26-09-10 $14.32 +0.42% 1,064,551
26-09-09 $14.26 -0.07% 1,146,124
26-09-08 $14.27 +3.11% 1,197,280
26-09-04 $13.84 -3.76% 804,585
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
14.07USD
Average target price
28.50USD
Spread / Average Target
+102.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLUE Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!